Twyneo Shortage: What Providers and Prescribers Need to Know in 2026

Patients calling your office to report they can't find Twyneo at their pharmacy is becoming a common occurrence. While Twyneo is not on the FDA's official drug shortage list as of 2026, the availability challenges your patients face are real — and as the prescriber, you play a key role in helping them navigate the situation. This guide provides clinical context and practical guidance for dermatologists, primary care physicians, and other prescribers.

Current Availability Status of Twyneo (2026)

Twyneo (tretinoin 0.1%/benzoyl peroxide 3% cream) is not listed on the FDA drug shortage database or the ASHP shortage list. The manufacturer, Mayne Pharma (a licensee of Sol-Gel Technologies), continues to supply the product. The availability problem is at the retail pharmacy level, not at the manufacturing level.

As a brand-name-only specialty dermatology product with a relatively small prescribing base and high retail cost (~$797 per 30g pump), many retail pharmacies have elected not to stock Twyneo routinely. This creates a de facto access gap for patients who may not know to check multiple pharmacies or request a special order.

Why Patients Are Calling Your Office About Twyneo

Your patients may contact your office for several reasons related to Twyneo availability:

Pharmacy doesn't carry it and refuses to special-order it

Insurance requiring prior authorization that was denied or is pending

Out-of-pocket cost being prohibitive even with manufacturer savings card

Prescription transferred to a different pharmacy that then couldn't fill it either

Clinical Background: What Makes Twyneo Different

Twyneo received FDA approval in July 2021 based on two phase 3 double-blind vehicle-controlled trials. In the first trial (NCT03761784), 38.5% of patients treated with Twyneo achieved IGA success (at least a 2-grade reduction from baseline to clear or almost clear) at 12 weeks, compared to 11.5% in the vehicle group. The formulation uses patented silica microencapsulation to stabilize tretinoin against degradation by benzoyl peroxide — a fundamental chemical incompatibility that previously prevented the two ingredients from being combined.

This microencapsulation technology is patent-protected through 2038, meaning no generic product can replicate the exact formulation. However, the clinical goals of combining a retinoid with an antimicrobial agent can be achieved through alternative formulations.

Clinically Appropriate Alternatives When Twyneo Is Unavailable

When Twyneo is inaccessible, the following alternatives maintain the dual-mechanism approach of combining a retinoid with an antimicrobial:

Adapalene 0.1% / Benzoyl Peroxide 2.5% (generic of Epiduo): Widely available, low cost, FDA-approved for acne vulgaris. A reasonable first substitute when Twyneo isn't accessible. Generally better tolerated than tretinoin-based formulations for sensitive skin.

Adapalene 0.3% / Benzoyl Peroxide 2.5% (generic of Epiduo Forte): For moderate-to-severe acne requiring higher retinoid potency.

Tretinoin (generic) + Benzoyl Peroxide (generic) as split regimen: Applied at different times of day to avoid in situ chemical interaction. Cost-effective and widely available.

Aklief (trifarotene cream 0.005%): Fourth-generation retinoid with RAR-gamma selectivity; FDA-approved for truncal acne as well as facial acne.

Winlevi (clascoterone 1% cream): Topical anti-androgen for patients with hormonally-driven acne or significant sensitivity to retinoids/BPO.

Managing Prior Authorization for Twyneo

Many commercial payers require prior authorization for Twyneo or require step therapy documentation demonstrating that lower-cost alternatives were tried first. When submitting a PA request:

Document prior failure of or contraindication to covered alternatives (e.g., adapalene/BPO generic)

Include clinical rationale for choosing tretinoin over adapalene (e.g., prior adapalene failure, retinoid resistance pattern)

Cite Twyneo's unique microencapsulation technology and clinical trial IGA success data if insurer challenges medical necessity

Supporting Your Patients With Cost and Access

When patients call about difficulty filling Twyneo, the most helpful actions are:

Inform patients about the Mayne Pharma Patient Savings Card: as little as $0 with commercial insurance or $45 cash-pay. Card available at twyneo.com/savings-support.

Recommend that patients use medfinder to locate a pharmacy that has it in stock — this avoids hours of phone calls on the patient's part.

Keep a small supply of office samples to bridge patients while they resolve access issues.

If using a preferred pharmacy — one you know reliably stocks Twyneo — e-prescribe there directly to avoid the prescription-transfer delay.

For more on integrating medfinder into your patient workflow, visit medfinder for providers.

Key Clinical Safety Reminders for Twyneo

Contraindicated in patients with a history of serious hypersensitivity to benzoyl peroxide or any Twyneo component.

Photosensitivity: Counsel patients to use sunscreen and minimize UV exposure during treatment.

Pregnancy category: Topical tretinoin — available data from observational studies have not established a drug-associated risk, but tretinoin animal data showed teratogenicity at high systemic doses. Use with caution in pregnancy.

Shelf life: 12 weeks from dispensing or 60 days from opening — whichever comes first. Counsel patients on proper storage (room temperature 68–77°F after dispensing).